Docetaxel, Irinotecan, and Carboplatin in Extensive Stage Non-Small Cell Lung Cancer
NCT00264134
Terminated
Primary Objective: To determine the maximum tolerated dose of docetaxel when given with Irinotecan and Carboplatin for the treatment of inoperable lung cancer. Secondary Objective: To evaluate the dose-related toxicities of this triple regimen in patients with inoperable lung cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/18/2010
Locations: Kentuckiana Cancer Institute, Louisville, Kentucky
Conditions: Non-small Cell Lung Cancer, Extensive Stage Unresectable
Register for Updates
Phase I-II Study of Carboplatin, Vinorelbine and Capecitabine in Patients With Metastatic Breast Cancer
NCT00277069
Completed
1. Determine the response rate with this regimen in an anthracycline and taxane resistant cohort of patients.
Gender:
FEMALE
Ages:
Between 18 years and 75 years
Trial Updated:
01/06/2010
Locations: University of New Mexico, Albuquerque, New Mexico
Conditions: Breast, Cancer
Register for Updates
Celecoxib, Paclitaxel, and Carboplatin in Treating Patients With Cancer of the Esophagus
NCT00066716
Completed
RATIONALE: Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop tumor cells from dividing so they stop growing or die. Celecoxib may increase the effectiveness of a chemotherapy drug by making tumor cells more sensitive to the drug. Celecoxib may also stop the growth of tumor cells by stopping blood flow to the tumor and/or may block the enzymes necessary for their growth. Combining celecoxib with paclitaxel and carboplatin before surgery may shrink the... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/07/2009
Locations: New York Weill Cornell Cancer Center at Cornell University, New York, New York
Conditions: Esophageal Cancer
Register for Updates
A Study of Docetaxel Plus Carboplatin in Patients With Hormone Refractory Prostate Cancer
NCT00134706
Completed
The purpose of this study is to look at the effects (good and bad) of the combination of docetaxel and carboplatin for patients who have progressive prostate cancer after chemotherapy with drugs such as docetaxel. The investigators are also studying whether the measurement of two proteins in the blood may predict who will respond to the combination of docetaxel and carboplatin.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
12/07/2009
Locations: Massachusetts General Hospital, Boston, Massachusetts +5 locations
Conditions: Prostate Cancer
Register for Updates
Carboplatin, Capecitabine, and Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer
NCT00114153
Completed
RATIONALE: Drugs used in chemotherapy, such as carboplatin and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving chemotherapy together with radiation therapy may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of capecitabine when given together with carboplatin followed by radiation therapy in tr... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/25/2009
Locations: University of Virginia Cancer Center at UV Health System, Charlottesville, Virginia
Conditions: Head and Neck Cancer
Register for Updates
A Study of Gemcitabine and Carboplatin (Plus Herceptin in Human Epidermal Growth Factor Receptor 2 Positive [HER2+] Patients) With Metastatic Breast Cancer
NCT00191451
Completed
The purposes of this study are to determine the safety of gemcitabine and paraplatin either with or without trastuzumab Any side effects that might be associated with these compounds. Whether the two or three drugs listed above when given in combination can help patients with metastatic breast cancer. How long the treatment will stop the growth of the cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/17/2009
Locations: For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Indianapolis, Indiana
Conditions: Breast Cancer
Register for Updates
Intensive Chemo-Radiotherapy With Peripheral Blood Progenitor Cell Rescue for Children With Advanced Neuroblastoma and Sarcomas
NCT00165139
Completed
The main purpose of this study is to determine the short and long term side effects of a very intensive treatment, which includes combinations of chemotherapy drugs followed by radiation therapy and two transplants supported by peripheral blood progenitor cells (stem cells), for children with advanced stage neuroblastoma and sarcomas.
Gender:
ALL
Ages:
19 years and below
Trial Updated:
10/30/2009
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts
Conditions: Neuroblastoma, Ewings Sarcoma, Non-rhabdomyosarcoma Soft Tissue Sarcoma
Register for Updates
Study of Pemetrexed and Carboplatin Compared With Etoposide Carboplatin to Treat Extensive-Stage Small Cell Lung Cancer
NCT00363415
Completed
This study is a Phase 3, global, multi-center, open-label study of patients with extensive-stage small cell lung cancer. Eligible patients will be randomly assigned to receive either pemetrexed plus carboplatin or etoposide plus carboplatin. It is anticipated that pemetrexed plus carboplatin will offer similar survival benefits as compared to etoposide plus carboplatin.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/20/2009
Locations: For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Huntsville, Alabama +189 locations
Conditions: Small Cell Lung Cancer
Register for Updates
Carboplatin in Patients With Progressive Gliomas
NCT00002749
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of carboplatin in patients with progressive glioma.
Gender:
ALL
Ages:
All
Trial Updated:
10/12/2009
Locations: Duke Comprehensive Cancer Center, Durham, North Carolina +1 locations
Conditions: Brain and Central Nervous System Tumors
Register for Updates
Randomized Ph 2 Trial Of Paclitaxel/Carboplatin /Bevacizumab + PF-3512676 And P/C/B Alone In Advanced Nonsquamous NSCLC
NCT00313768
Terminated
To assess the efficacy and safety of PF-3512676 administered in combination with paclitaxel, carboplatin and bevacizumab as first-line treatment in patients with locally advanced or metastatic nonsquamous non-small cell lung cancer
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/24/2009
Locations: Pfizer Investigational Site, Bessemer, Alabama +28 locations
Conditions: Carcinoma, Non-Small-Cell Lung
Register for Updates
Therapy for Children With Advanced Stage High Risk Neuroblastoma
NCT00186849
Completed
This is a Phase II pilot study of chemotherapy and surgery for children with advanced stage high-risk neuroblastoma utilizing topotecan during an upfront window and other active agents during induction and intensification phases. The primary purpose is to estimate the response rate to an upfront window of two cycles of intravenous topotecan. We hypothesize that the topotecan window will be an effective therapy in terms of the response rate.
Gender:
ALL
Ages:
18 years and below
Trial Updated:
05/19/2009
Locations: St. Jude Children's Research Hospital, Memphis, Tennessee
Conditions: Neuroblastoma
Register for Updates
Gemcitabine/Oxaliplatin (GEMOX) vs Carboplatin/Paclitaxel (CP) in Non-Small Cell Lung Cancer (NSCLC)
NCT00087802
Completed
The purpose of this study is to compare combination treatment of gemcitabine + oxaliplatin (GEMOX) with carboplatin + paclitaxel (CP) to determine if there is a difference in response and safety between the two drug combinations for the treatment of advanced non-small cell lung cancer (NSCLC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/15/2009
Locations: Birmingham Hematology and Oncology Associates, LLC, Birmingham, Alabama +69 locations
Conditions: Carcinoma, Non-Small-Cell Lung
Register for Updates